Gene
SERPINB3
SERPINB3 is a gene biomarker in the evidence tier "Cancer actionable (CGI)". This page lists evidence by type: Assay-provider ledger (27), Actionable biomarkers (1), Trial mentions (55), and 5 more evidence types, each linked to its source.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Rows recorded per section (log scale)
4 sections measured, none recorded
Cancer actionable (CGI)
Evidence over time
Share of that year: what fraction of the trials and papers our biomarker dictionary matched in a year mention SERPINB3. The denominator is documents that mention any gene, not every registered document, so improving the matcher moves both halves and never rewrites history. Gene named in free-text trial records. A mention, not a validated biomarker. Actionable-biomarker and target-disease-association evidence carries no date in our sources, so it is not on this chart. Publication mentions cover only papers cited by a registered clinical trial, not all of PubMed.
Trial mentions: plotted from 1990 to 2026, the years our matched corpus covers. Not plotted: 1 with a planned future start.
Publication mentions: plotted from 1990 to 2023, the years our matched corpus covers. Not plotted: 1 at the structurally incomplete recent edge.
The yearly numbers
| Year | Trial mentions | Share of that year | Publication mentions | Share of that year |
|---|---|---|---|---|
| 2026 | 0 of 8,738 | 0.00% | not measured | |
| 2025 | 0 of 8,875 | 0.00% | not measured | |
| 2024 | 1 of 8,597 | 0.01% | not measured | |
| 2023 | 2 of 8,275 | 0.02% | 8 of 11,460 | 0.07% |
| 2022 | 2 of 8,285 | 0.02% | 7 of 13,598 | 0.05% |
| 2021 | 1 of 8,692 | 0.01% | 8 of 15,045 | 0.05% |
| 2020 | 5 of 7,640 | 0.07% | 4 of 14,459 | 0.03% |
| 2019 | 5 of 7,300 | 0.07% | 5 of 12,159 | 0.04% |
| 2018 | 6 of 6,927 | 0.09% | 11 of 11,854 | 0.09% |
| 2017 | 2 of 6,558 | 0.03% | 4 of 11,595 | 0.03% |
Showing 10 of 37 years.
Assay-provider ledger (27)
Shown in this order: most recent publication first.
| Company | Provider class | Validation | Papers | Most recent publication |
|---|---|---|---|---|
| BECKMAN COULTER | Context dependent | Clinical validation | 1 | February 01, 2026 |
| Deepwise | Unclassified | Clinical validation | 1 | February 01, 2026 |
| Shenzhen Mindray Bio-Medical Electronics Co. | Unclassified | Clinical validation | 1 | February 01, 2026 |
| Shenrui Medical | Diagnostic provider | Clinical validation | 1 | March 01, 2025 |
| ROCHE | Context dependent | Clinical validation | 5 | January 01, 2025 +2 undated |
Showing 5 of 27 assay-provider companies.
Actionable biomarkers (1)
Shown in this order: fixed catalogue order, not ranked.
| Alteration | Drug | Response | Disease | Source |
|---|---|---|---|---|
| SERPINB3 oncogenic mutation | Ctla4 Inhibitors | response-associated | cutaneous melanoma | Cancer Genome Interpreter |
Trial mentions (55)
Shown in this order: fixed catalogue order, not by date.
| Trial | Source |
|---|---|
| NCT06105177 | Trial biospecimen (AACT) |
| NCT03277729 | Trial eligibility (AACT) |
| NCT03502577 | Trial eligibility (AACT) |
| NCT00564733 | Trial eligibility (AACT) |
| NCT03519295 | Trial eligibility (AACT) |
Showing 5 of 55 trial mentions.
Target-disease associations (85)
Shown in this order: fixed catalogue order, not ranked.
| Disease | Therapeutic area | Source |
|---|---|---|
| Alzheimer disease | nervous system disease | Literature (Europe PMC) |
| COVID-19 | infectious disease | Expression Atlas |
| Cirrhosis | phenotype | Literature (Europe PMC) |
| Hepatic fibrosis | phenotype | Literature (Europe PMC) |
| Neoplasm of the liver | phenotype | Literature (Europe PMC) |
Showing 5 of 85 associations.
Vendor sourcing (212)
Shown in this order: alphabetical by organization.
| Organization | Role | Tier | Evidence | Citation |
|---|---|---|---|---|
| Aarhus University Hospital | Trial sponsor | Named in trial inclusion criteriaTrial eligibility criteria | : * Patients with SCCA eligible for definitive (chemo)radiotherapy * ≥ 18 of years * Written and oral consent | View trial NCT05572801 |
| Aarhus University Hospital | Trial sponsor | Mentioned in trial textTrial free-text mention | SCCA | View trial NCT05572801 |
| Affini-T Therapeutics, Inc. | Trial collaborator | Named in trial inclusion criteriaTrial eligibility criteria | : * EVALUATION: Metastatic or unresectable Merkel cell polyomavirus (MCPyV)-associated Merkel cell carcinoma (VP-MCC) that has progressed on or after prior ... | View trial NCT03747484 |
| Affini-T Therapeutics, Inc. | Trial collaborator | Mentioned in trial textTrial free-text mention | SCCA | View trial NCT03747484 |
| Ambry Genetics (United States) | Testing lab / CRO (runs the assay) | Clinical-testing interpretation submitted (ClinVar)ClinVar clinical-testing submission | The c.263T>C (p.L88P) alteration is located in exon 4 (coding exon 3) of the SERPINB3 gene. This alteration results from a T to C substitution at nucleotide ... | View ClinVar record SCV003540694.3 |
Showing 5 of 212 sourcing records.
Trial-cited literature (77)
Shown in this order: newest first, then most cited.
| Publication | Journal | Year | Citations |
|---|---|---|---|
| Robotic versus Electromagnetic bronchoscopy for pulmonary LesIon AssessmeNT: the RELIANT pragmatic randomized trial. | Trials | 2024 | 19 |
| Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. | The Cochrane database of systematic reviews | 2023 | 68 |
| Lattice Radiation Therapy in clinical practice: A systematic review. | Clinical and translational radiation oncology | 2023 | 64 |
| Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer. | Frontiers in immunology | 2023 | 9 |
| Pucotenlimab in patients with advanced mismatch repair-deficient or microsatellite instability-high solid tumors: A multicenter phase 2 study. | Cell reports. Medicine | 2023 | 8 |
Showing 5 of 77 papers.
Literature-extracted relations (8)
Shown in this order: chemicals, then diseases.
| Related entity | Kind | Source relation label | Paper | Year |
|---|---|---|---|---|
| Neoplasms | Disease | associate |
Identification and validation of a dysregulated TME-related gene signature for predicting prognosis, and immunological properties in bladder cancer. | 2023 |
| Fibromyalgia | Disease | associate |
Metabolomic and proteomic characterization of sng and pain phenotypes in fibromyalgia. | 2022 |
| Neoplasm Metastasis | Disease | associate |
Establishment and validation of a novel survival prediction scoring algorithm for patients with non-small-cell lung cancer spinal metastasis. | 2019 |
| Lung Neoplasms | Disease | associate |
Probability of cancer in high-risk patients predicted by the protein-based lung cancer biomarker panel in China: LCBP study. | 2018 |
| Digital Dermatitis | Disease | associate |
Serum squamous cell carcinoma antigen is a useful biologic marker in patients with inverted papillomas of the sinonasal tract. | 2002 |
Showing 5 of 8 relation assertions.
Organizations publishing (109)
Shown in this order: most papers first.
| Organization | Type | Papers | Years |
|---|---|---|---|
| Memorial Sloan Kettering Cancer Center | Hospital | 6 | 2016 to 2022 |
| Fudan University | Academic | 4 | 2018 to 2023 |
| Seoul National University | Academic | 4 | 2020 to 2021 |
| University of London | Academic | 4 | 2015 to 2021 |
| Children's Hospital of Fudan University | Hospital | 3 | 2022 to 2023 |
Showing 5 of 109 organizations.
Where SERPINB3 appears
- biological_process
- cancer or benign tumor
- cardiovascular disease
- endocrine system disease
- gastrointestinal disease
- genetic, familial or congenital disease
- hematologic disease
- immune system disease
- infectious disease
- integumentary system disease
- measurement
- musculoskeletal or connective tissue disease
- nervous system disease
- phenotype
- respiratory or thoracic disease
- urinary system disease
81 diseases touched.
Not on this page
Checked, with nothing recorded for this biomarker: fda companion diagnostic assertions, fda biomarker qualification projects, protein variant mentions, and human sample screening reference.